Lymph liquid biopsy:
Novel. Near. Now.


For the first time, non-invasive liquid biopsy techniques can unlock lymphatic insights to aid in post-operative treatment decisions.

The lymphatic system is the most common means of metastasis in over 90% of cancer cases. Lymphatic metastasis begins in the nodes nearest the tumor where cancer cells can grow and eventually spread via the circulatory system.

Primary means of
metastasis by cancer type

  • Breast
  • Prostate
  • Lung
  • Colorectal
  • Melanoma
  • Bladder
  • Renal
  • Uterine
  • Pancreatic
  • Head and neck
  • Thyroid
  • Liver
  • Stomach
  • Esophageal
  • Blood
  • Bone
  • Sarcoma
  • Ovarian/fallopian


Understanding local risk requires a local analyte.  Lymph-rich surgical drain fluid is the most proximal biofluid to the recently resected tumor, enabling assessment of recurrence risk before cancer spreads.

Droplet sequences the fluid that drains from an integrated network of tissue, nodes, and lymphatic channels in the locoregional area.

Droplet’s assay can detect molecular-level disease, in-transit metastasis, and positive nodes that may have been missed during surgery or pathological review.


Droplet delivers highly sensitive results early enough to aid in treatment decisions during the curative timeframe.

Blood-based ctDNA markers of minimal residual disease can identify recurrence but rarely in time to impact treatment with curative intent or with the sensitivity necessary to detect locoregional spread.

Lymph liquid biopsy takes place immediately after surgery, allowing care teams to assess metastatic risk at the most consequential time point and design adjuvant treatment plans for every individual patient.


AACR 2024: Detection of minimal residual disease in lymph predicts recurrence in HPV-negative head and neck cancer patients
MHNCS 2024: Detection of minimal residual disease in post-surgical drain fluid synergizes with pathology to predict recurrence in HPV-negative head and neck cancer patients
Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Detection of Locoregional Minimal Residual Disease Immediately After Surgery Through Multi-Omic Analysis of Tumor-Associated Cell-Free DNA in Surgical Drain Fluid
Surgical Drain Fluid as a Novel Liquid Biopsy Analyte to Measure Postoperative Minimal Residual Disease in HPV+ Oropharyngeal Cancer